Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA.
Department of Orthopedic Surgery, Cleveland Clinic, Cleveland, OH, USA.
Regen Med. 2019 Jul;14(7):639-646. doi: 10.2217/rme-2018-0173. Epub 2019 Jul 19.
A limiting factor in advancement of bone marrow based cell therapies is the lack of characterization of cell products delivered to patients. Using an automated hematology analyzer that can be implemented in clinical setting, the composition of bone marrow aspirates (n = 17 patients) and bone marrow concentrates (n = 12 patients) were assessed. ICC estimates were calculated for measuring reliability. Bone marrow aspirates assessment resulted in excellent reliability for determining white blood cells (ICC - 0.96; 95% CI: 0.92-0.99), red blood cells (ICC - 0.9; 95% CI: 0.77-0.96), platelets (ICC - 0.93; 95% CI: 0.85-0.97) composition. Bone marrow concentrate assessment resulted in excellent reliability for determining white blood cells (ICC - 0.97; 95% CI: 0.93-0.99), platelets (ICC - 0.95; 95% CI: 0.89-0.99) and moderate reliability for red blood cells (ICC - 0.66; 95% CI: 0.36-0.87) composition. Modern automated hematology analyzers could assist to better characterize the cell therapy products to provide reliable and consistent outcomes.
骨髓细胞疗法进展的一个限制因素是缺乏对输送给患者的细胞产品的特征描述。本研究使用一种可在临床环境中实施的自动化血液分析仪，评估了骨髓抽吸物（n=17 例患者）和骨髓浓缩物（n=12 例患者）的组成。计算了 ICC 估计值以衡量可靠性。骨髓抽吸物评估在确定白细胞（ICC-0.96；95%CI：0.92-0.99）、红细胞（ICC-0.9；95%CI：0.77-0.96）和血小板（ICC-0.93；95%CI：0.85-0.97）组成方面具有极好的可靠性。骨髓浓缩物评估在确定白细胞（ICC-0.97；95%CI：0.93-0.99）、血小板（ICC-0.95；95%CI：0.89-0.99）方面具有极好的可靠性，在确定红细胞（ICC-0.66；95%CI：0.36-0.87）方面具有中度可靠性。现代自动化血液分析仪可以帮助更好地描述细胞治疗产品，提供可靠和一致的结果。
